CompletedNot Applicable

Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19

France100 participantsStarted 2020-04-01

Plain-language summary

Describe COVID-19 patients who are receiving ECMO-VV respiratory replacement and what happens to them.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient over the age of 18; * Diagnostic COVID-19 by RT-PCR; * Hospitalisation in resuscitation for the management of complications related to COVID-19 * Implanted ECMO-VV during hospitalisation; * Patient agreeing to participate in the study Exclusion Criteria: * Sujet under guardianship or trusteeship * Sujet under safeguard of justice

What they're measuring

Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them

Timeframe: Files analysed retrospectily from March 1st, 2020 to April 15, 2020 will be examined

Trial details

NCT IDNCT04343404

SponsorUniversity Hospital, Strasbourg, France

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-04-15

View on ClinicalTrials.gov More Respiratory Distress Syndrome trials